Overview

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

Status:
Unknown status

Trial end date:
2019-03-01

Target enrollment:

Participant gender:

Summary

This study will look at effects the combination of palbociclib and letrozole may have on estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer tumors which have not yet been treated. Letrozole is a type of endocrine therapy called an aromatase inhibitor (AI) and is standard treatment for post-menopausal women with ER-positive/HER2-negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

NSABP Foundation Inc

Collaborators:

Institute of Cancer Research, United Kingdom
Pfizer
Royal Marsden NHS Foundation Trust

Treatments:

Estrogens
Letrozole
Palbociclib